|
Gene: DERA |
Gene summary for DERA |
Gene summary. |
Gene information | Species | Human | Gene symbol | DERA | Gene ID | 51071 |
Gene name | deoxyribose-phosphate aldolase | |
Gene Alias | CGI-26 | |
Cytomap | 12p12.3 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | E9PPM8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51071 | DERA | CCI_1 | Human | Cervix | CC | 2.35e-02 | 5.71e-01 | 0.528 |
51071 | DERA | CCI_2 | Human | Cervix | CC | 4.67e-04 | 6.65e-01 | 0.5249 |
51071 | DERA | CCI_3 | Human | Cervix | CC | 8.73e-08 | 7.48e-01 | 0.516 |
51071 | DERA | sample3 | Human | Cervix | CC | 4.94e-04 | 2.10e-01 | 0.1387 |
51071 | DERA | LZE2T | Human | Esophagus | ESCC | 1.44e-03 | 5.40e-01 | 0.082 |
51071 | DERA | LZE3D | Human | Esophagus | HGIN | 6.52e-03 | 5.66e-01 | 0.0668 |
51071 | DERA | LZE4T | Human | Esophagus | ESCC | 5.76e-11 | 3.03e-01 | 0.0811 |
51071 | DERA | LZE5T | Human | Esophagus | ESCC | 1.31e-05 | 4.02e-01 | 0.0514 |
51071 | DERA | LZE7T | Human | Esophagus | ESCC | 5.73e-07 | 6.37e-01 | 0.0667 |
51071 | DERA | LZE8T | Human | Esophagus | ESCC | 4.91e-23 | 7.27e-01 | 0.067 |
51071 | DERA | LZE20T | Human | Esophagus | ESCC | 4.12e-09 | 3.06e-01 | 0.0662 |
51071 | DERA | LZE22D1 | Human | Esophagus | HGIN | 1.25e-03 | 1.44e-01 | 0.0595 |
51071 | DERA | LZE22T | Human | Esophagus | ESCC | 2.40e-02 | 4.26e-01 | 0.068 |
51071 | DERA | LZE24T | Human | Esophagus | ESCC | 2.65e-20 | 5.32e-01 | 0.0596 |
51071 | DERA | LZE21T | Human | Esophagus | ESCC | 2.19e-06 | 5.62e-01 | 0.0655 |
51071 | DERA | LZE6T | Human | Esophagus | ESCC | 1.64e-08 | 2.84e-01 | 0.0845 |
51071 | DERA | P2T-E | Human | Esophagus | ESCC | 1.86e-41 | 8.39e-01 | 0.1177 |
51071 | DERA | P4T-E | Human | Esophagus | ESCC | 3.05e-41 | 1.09e+00 | 0.1323 |
51071 | DERA | P5T-E | Human | Esophagus | ESCC | 6.42e-25 | 5.95e-01 | 0.1327 |
51071 | DERA | P8T-E | Human | Esophagus | ESCC | 1.85e-36 | 6.69e-01 | 0.0889 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190136119 | Skin | AK | organic cyclic compound catabolic process | 67/1910 | 495/18723 | 9.91e-03 | 4.80e-02 | 67 |
GO:0006091111 | Skin | cSCC | generation of precursor metabolites and energy | 224/4864 | 490/18723 | 1.13e-21 | 2.21e-19 | 224 |
GO:0034655111 | Skin | cSCC | nucleobase-containing compound catabolic process | 172/4864 | 407/18723 | 4.11e-13 | 2.43e-11 | 172 |
GO:0046700110 | Skin | cSCC | heterocycle catabolic process | 178/4864 | 445/18723 | 4.45e-11 | 2.13e-09 | 178 |
GO:0044270110 | Skin | cSCC | cellular nitrogen compound catabolic process | 179/4864 | 451/18723 | 8.34e-11 | 3.79e-09 | 179 |
GO:0019439110 | Skin | cSCC | aromatic compound catabolic process | 183/4864 | 467/18723 | 1.76e-10 | 7.68e-09 | 183 |
GO:1901361110 | Skin | cSCC | organic cyclic compound catabolic process | 188/4864 | 495/18723 | 1.92e-09 | 7.01e-08 | 188 |
GO:000675324 | Skin | cSCC | nucleoside phosphate metabolic process | 176/4864 | 497/18723 | 1.55e-06 | 2.62e-05 | 176 |
GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
GO:00092625 | Skin | cSCC | deoxyribonucleotide metabolic process | 22/4864 | 44/18723 | 5.41e-04 | 4.01e-03 | 22 |
GO:00196925 | Skin | cSCC | deoxyribose phosphate metabolic process | 21/4864 | 42/18723 | 7.20e-04 | 5.05e-03 | 21 |
GO:19016575 | Skin | cSCC | glycosyl compound metabolic process | 37/4864 | 88/18723 | 7.39e-04 | 5.15e-03 | 37 |
GO:00091164 | Skin | cSCC | nucleoside metabolic process | 27/4864 | 62/18723 | 1.99e-03 | 1.19e-02 | 27 |
GO:00060984 | Skin | cSCC | pentose-phosphate shunt | 9/4864 | 15/18723 | 5.52e-03 | 2.73e-02 | 9 |
GO:00067404 | Skin | cSCC | NADPH regeneration | 9/4864 | 16/18723 | 9.73e-03 | 4.31e-02 | 9 |
GO:0006091112 | Thyroid | PTC | generation of precursor metabolites and energy | 252/5968 | 490/18723 | 8.24e-20 | 1.13e-17 | 252 |
GO:0034655112 | Thyroid | PTC | nucleobase-containing compound catabolic process | 211/5968 | 407/18723 | 2.72e-17 | 2.52e-15 | 211 |
GO:0046700111 | Thyroid | PTC | heterocycle catabolic process | 221/5968 | 445/18723 | 2.43e-15 | 1.72e-13 | 221 |
GO:0044270111 | Thyroid | PTC | cellular nitrogen compound catabolic process | 223/5968 | 451/18723 | 3.34e-15 | 2.31e-13 | 223 |
GO:0019439111 | Thyroid | PTC | aromatic compound catabolic process | 225/5968 | 467/18723 | 8.51e-14 | 4.71e-12 | 225 |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00030 | Liver | Cirrhotic | Pentose phosphate pathway | 16/2530 | 30/8465 | 6.04e-03 | 2.12e-02 | 1.30e-02 | 16 |
hsa000301 | Liver | Cirrhotic | Pentose phosphate pathway | 16/2530 | 30/8465 | 6.04e-03 | 2.12e-02 | 1.30e-02 | 16 |
hsa000302 | Liver | HCC | Pentose phosphate pathway | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
hsa000303 | Liver | HCC | Pentose phosphate pathway | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DERA | SNV | Missense_Mutation | rs775272940 | c.416N>A | p.Arg139Gln | p.R139Q | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DERA | SNV | Missense_Mutation | rs778363116 | c.536G>A | p.Arg179His | p.R179H | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-A6-5667-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
DERA | SNV | Missense_Mutation | rs760703237 | c.712N>T | p.Arg238Trp | p.R238W | Q9Y315 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DERA | SNV | Missense_Mutation | c.634G>A | p.Ala212Thr | p.A212T | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
DERA | SNV | Missense_Mutation | c.766G>A | p.Ala256Thr | p.A256T | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
DERA | SNV | Missense_Mutation | c.860N>A | p.Arg287Gln | p.R287Q | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
DERA | SNV | Missense_Mutation | c.860G>A | p.Arg287Gln | p.R287Q | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
DERA | SNV | Missense_Mutation | novel | c.893N>G | p.Glu298Gly | p.E298G | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DERA | SNV | Missense_Mutation | c.457G>A | p.Glu153Lys | p.E153K | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
DERA | SNV | Missense_Mutation | novel | c.292G>A | p.Ala98Thr | p.A98T | Q9Y315 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |